Hansoh Pharma (03692): HS-10587 tablets have obtained a drug clinical trial approval notification from the National Medical Products Administration.
Hans Pharmaceuticals (03692) announced that the Group's independently developed new drug HS-10587 tablets have received the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China, and plan to conduct clinical trials for advanced solid tumors with MTAP deficiency.
HANSOH PHARMA (03692) announced that the Group's independently developed new drug, HS-10587 tablets, has received the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China. The clinical trial is intended to be conducted for late-stage solid tumors with MTAP deficiency.
Related Articles
Historic moment! The first successful implementation of BNCT treatment in Hainan CH Biotech Co., Ltd. (08037) is revalued and industry breakthroughs.
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Historic moment! The first successful implementation of BNCT treatment in Hainan CH Biotech Co., Ltd. (08037) is revalued and industry breakthroughs.
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
